These 2 antagonistic properties of elevated Myc expression—supercompetition vs. apoptosis—make it difficult to predict the fates of high- vs. low-Myc–expressing cancer cells during tumor evolution in vivo. The gene discussed is MYC; the disease is neoplasm.